Samrina Hanif, MD
Neurology · Huntington, WVNPI 1992852719
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Livanova USA, Inc. at 53.8% of the total. Reporting peaked in 2023 at $4,450 and has fallen 60.0% since, to $1,781 in 2025.
Across 189 payments — averaging $63.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$6K
- Medtronic$2K
- AbbVie$1K
- Neurelis, Inc.$552
- UCB, Inc.$417
- SK Life Science, Inc.$168
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$6,02450%
- Travel & lodging$1,46212%
- Food & beverage$4,40137%
- Education$1061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 14 | $6,451 |
| Medtronic(2 entities) | 19 | $2,179 |
| AbbVie | 74 | $1,203 |
| Neurelis, Inc. | 12 | $552 |
| UCB, Inc. | 8 | $417 |
| SK Life Science, Inc. | 6 | $168 |
| Biogen | 6 | $114 |
| Acadia Pharmaceuticals Inc | 5 | $105 |
| Neurocrine Biosciences, Inc. | 6 | $105 |
| Merz Pharmaceuticals, LLC | 5 | $102 |
| Sunovion Pharmaceuticals Inc. | 4 | $71 |
| Pfizer | 4 | $67 |
| Lundbeck LLC | 4 | $66 |
| Amgen | 4 | $60 |
| Catalyst Pharmaceuticals, Inc. | 3 | $47 |
| Lilly USA, LLC | 3 | $38 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Argenx US, Inc. | 1 | $26 |
| EMD Serono, Inc. | 1 | $25 |
| Aquestive Therapeutics, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Sanofi | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$6,024
- ACTIVA$1,788
- VALTOCO$247
How this compares
$11,993 in reported general payments places this provider in the 80th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 106 | $171,887 |
| EpidiolexCannabidiol (Cbd) | 30 | $95,317 |
| FycompaPerampanel | 18 | $44,557 |
| TopamaxTopiramate | 11 | $39,713 |
| VimpatLacosamide | 19 | $37,453 |
| Lamictal XrLamotrigine | 13 | $30,086 |
| XcopriCenobamate | 24 | $29,999 |
| AptiomEslicarbazepine Acetate | 13 | $28,816 |
| Lacosamide | 251 | $25,110 |
| Levetiracetam | 618 | $25,047 |
| NayzilamMidazolam | 26 | $16,389 |
| Carbamazepine ErCarbamazepine | 44 | $13,472 |
| Oxcarbazepine | 106 | $11,199 |
| Divalproex Sodium ErDivalproex Sodium | 199 | $10,702 |
| OnfiClobazam | 11 | $9,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $417 | $225,729151 claims |
| SK Life Science, Inc.Xcopri | $168 | $29,99924 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $71 | $28,81613 claims |
| Lundbeck LLCOnfi | $66 | $9,20611 claims |
| PfizerDilantin | $67 | $7,14934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 93 neurology providers in West Virginia.
Other neurology in Huntington
- Paul FergusonHuntington$649K
- Ronald BareboHuntington$28K
- Lindsay LittlehalesHuntington$17K
- Suresh KumarHuntington$12K
- Kathryn ThorntonHuntington$3K
- Matthew BurtonHuntington$3K
- Justin NolteHuntington$2K
- Christopher BurrellHuntington$1K
- Dharampreet SinghHuntington$971
- Gabrielle ConwayHuntington$914
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.